With more people taking the weight-loss drugs Wegovy and Zepbound, one question inevitably arises: which one is more ...

Lilly's Zepbound surpasses Wegovy in dollar sales, while pricing cuts and copycats pressure Novo's growth outlook.

Losing weight with the help of a prescription weight loss drug continues to increase in popularity. According to recent KFF polls, about one in eight U.S. adults takes a GLP-1 medication for ...

Drugmaker Novo Nordisk plans to slash list prices for its wildly popular weight-loss and diabetes drugs Wegovy and Ozempic by ...

Novo Nordisk'sNVO oral Wegovy snagged 3,071 prescriptions in its first week on the market, an analyst said Friday. Novo Nordisk stock jumped on the news. In comparison, Eli Lilly'sLLY weight-loss shot ...

Eli Lilly announced on " Good Morning America " Monday that its GLP-1 weight-loss drug Zepbound will now be available in a new multi-dose KwikPen, giving patients a simpler way to receive a full month ...

Dietitian-designed, high-protein meals start at $8.99/serving — the most affordable dedicated GLP-1 meal delivery ...

Ozempic maker's lawsuit, FDA enforcement could curtail sales of less expensive, compounded, versions of popular weight loss ...

After finding itself some unwanted attention this week, Novo Nordisk (NYSE:NVO) has dropped 22% in the past week and 56% over ...